recombinant mouse ifn λ2 (R&D Systems)
R&D Systems is a verified supplier 
R&D Systems manufactures this product 
94
Structured Review
R&D Systems
recombinant mouse ifn λ2
Recombinant Mouse Ifn λ2, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 29 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+mouse+ifn+%CE%BB2/Recombinant+Mouse+IFN-epsilon+Protein/pmc12519780-52-16-21
Average 94 stars, based on 29 article reviews
Recombinant Mouse Ifn λ2, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 29 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+mouse+ifn+%CE%BB2/Recombinant+Mouse+IFN-epsilon+Protein/pmc12519780-52-16-21
Average 94 stars, based on 29 article reviews
recombinant mouse ifn λ2 - by Bioz Stars,
2026-11
94/100 stars
Images
Related Articles
In Vitro:Article Title: Myeloid cell-specific type I interferon signaling mediates age-dependent inflammation and protection in Bordetella pertussis infection. Article Snippet: .. For in vitro stimulation, neutrophils or macrophages (2 × 106 cells/mL) were pretreated with 100 ng/mL Article Title: Myeloid cell-specific type I interferon signaling mediates age-dependent inflammation and protection in Bordetella pertussis infection Article Snippet: .. For in vitro stimulation, neutrophils or macrophages (2 × 106 cells/mL) were pretreated with 100 ng/mL Recombinant:Article Title: Myeloid cell-specific type I interferon signaling mediates age-dependent inflammation and protection in Bordetella pertussis infection. Article Snippet: .. For in vitro stimulation, neutrophils or macrophages (2 × 106 cells/mL) were pretreated with 100 ng/mL Article Title: Reducing off-target drug accumulation by exploiting a type-III interferon response. Article Snippet: Nanomedicines have been touted as the future of cancer therapy for decades.. However, the field of tumortargeted nanomedicine has failed to significantly advance toward becoming the primary choice for cancer intervention.. One of the largest obstacles that has yet to be overcome is off-target accumulation of the nanoparticles. Article Title: Exploiting a type III interferon response to improve chemotherapeutic safety and efficacy Article Snippet: .. Each mouse received a single dose of 200 μL 1x PBS, 10 μg of Article Title: Exploiting a Type III Interferon Response to Improve Chemotherapeutic Safety and Efficacy Article Snippet: .. Each mouse received a single dose of 200 μL 1x PBS, 10 μg of Article Title: Exploiting a Type III Interferon Response to Improve Chemotherapeutic Safety and Efficacy. Article Snippet: .. Each mouse received a single dose of 200 μL 1x PBS, 10 μg of Article Title: Myeloid cell-specific type I interferon signaling mediates age-dependent inflammation and protection in Bordetella pertussis infection Article Snippet: .. For in vitro stimulation, neutrophils or macrophages (2 × 106 cells/mL) were pretreated with 100 ng/mL Liposomes:Article Title: Reducing off-target drug accumulation by exploiting a type-III interferon response. Article Snippet: Nanomedicines have been touted as the future of cancer therapy for decades.. However, the field of tumortargeted nanomedicine has failed to significantly advance toward becoming the primary choice for cancer intervention.. One of the largest obstacles that has yet to be overcome is off-target accumulation of the nanoparticles. Injection:Article Title: Reducing off-target drug accumulation by exploiting a type-III interferon response. Article Snippet: Nanomedicines have been touted as the future of cancer therapy for decades.. However, the field of tumortargeted nanomedicine has failed to significantly advance toward becoming the primary choice for cancer intervention.. One of the largest obstacles that has yet to be overcome is off-target accumulation of the nanoparticles. Article Title: Exploiting a type III interferon response to improve chemotherapeutic safety and efficacy Article Snippet: .. Each mouse received a single dose of 200 μL 1x PBS, 10 μg of Article Title: Exploiting a Type III Interferon Response to Improve Chemotherapeutic Safety and Efficacy Article Snippet: .. Each mouse received a single dose of 200 μL 1x PBS, 10 μg of Article Title: Exploiting a Type III Interferon Response to Improve Chemotherapeutic Safety and Efficacy. Article Snippet: .. Each mouse received a single dose of 200 μL 1x PBS, 10 μg of |